HK1168284A1 - Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units - Google Patents

Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units

Info

Publication number
HK1168284A1
HK1168284A1 HK12109099.7A HK12109099A HK1168284A1 HK 1168284 A1 HK1168284 A1 HK 1168284A1 HK 12109099 A HK12109099 A HK 12109099A HK 1168284 A1 HK1168284 A1 HK 1168284A1
Authority
HK
Hong Kong
Prior art keywords
pth
osteoporosis
week
units
unit dose
Prior art date
Application number
HK12109099.7A
Other languages
English (en)
Inventor
Shinichiro Shirae
Yasuo Nakamura
Yuiko Masunaga
Yoshihide Nozaki
Nobuyuki Kobayashi
Tatsuhiko Kuroda
Hiroki Kato
Masashi Serada
Kazuyoshi Hori
Original Assignee
Asahi Kasei Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43732444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1168284(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asahi Kasei Pharma Corp filed Critical Asahi Kasei Pharma Corp
Publication of HK1168284A1 publication Critical patent/HK1168284A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK12109099.7A 2009-09-09 2012-09-17 Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units HK1168284A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009208039 2009-09-09
PCT/JP2010/065379 WO2011030774A1 (ja) 2009-09-09 2010-09-08 １回当たり１００～２００単位のｐｔｈが週１回投与されることを特徴とする、ｐｔｈ含有骨粗鬆症治療／予防剤

Publications (1)

Publication Number Publication Date
HK1168284A1 true HK1168284A1 (en) 2012-12-28

Family

ID=43732444

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12109099.7A HK1168284A1 (en) 2009-09-09 2012-09-17 Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units

Country Status (17)

Country Link
US (3) US20120252729A1 (es)
EP (3) EP2476429B1 (es)
JP (13) JPWO2011030774A1 (es)
KR (8) KR20190095552A (es)
CN (2) CN103893746A (es)
AU (1) AU2010293488B2 (es)
BR (1) BR112012003511A2 (es)
CA (1) CA2772656A1 (es)
ES (3) ES2843649T3 (es)
HK (1) HK1168284A1 (es)
IL (1) IL217854A (es)
IN (1) IN2012DN00857A (es)
MX (1) MX335951B (es)
NZ (2) NZ598370A (es)
RU (1) RU2564894C2 (es)
WO (1) WO2011030774A1 (es)
ZA (1) ZA201201720B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2770340C (en) * 2009-11-18 2019-08-27 Asahi Kasei Pharma Corporation Preventive and/or therapeutic and/or aggravation suppressing agent for human arthritis deformans
JP6235219B2 (ja) * 2013-03-21 2017-11-22 旭化成ファーマ株式会社 脊椎椎体間固定術後の骨癒合促進剤
US10394953B2 (en) 2015-07-17 2019-08-27 Facebook, Inc. Meme detection in digital chatter analysis
EP3576774A4 (en) * 2017-02-01 2020-10-07 The Johns Hopkins University PARATHYROID HORMONE AND REGENERATION OF DEGENERATIVE DISCS
EP3685850A4 (en) * 2017-09-22 2021-06-16 Asahi Kasei Pharma Corporation LIQUID PHARMACEUTICAL COMPOSITION CONTAINING TRIPARATIDE WITH EXCELLENT PHARMACODYNAMIC PROPERTIES AND / OR STABILITY
JP2019060866A (ja) * 2017-09-22 2019-04-18 旭化成ファーマ株式会社 液状医薬組成物の体内動態を予測する方法
JP6577683B2 (ja) * 2017-09-22 2019-09-18 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
JP7080487B2 (ja) 2018-09-26 2022-06-06 東陽建設工機株式会社 鉄筋曲げ方法
CN111447943A (zh) 2018-10-29 2020-07-24 旭化成制药株式会社 以按每周2次的频率给予特立帕肽或其盐为特征的骨质疏松症的预防或治疗方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2505812B2 (ja) 1987-07-10 1996-06-12 旭化成工業株式会社 ｈ―ＰＴＨ（１―３４）凍結乾燥組成物
JP2662842B2 (ja) 1991-12-09 1997-10-15 旭化成工業株式会社 パラサイロイドホルモンの安定化組成物
JPH0873376A (ja) * 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
ZA9811127B (en) * 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
AR033639A1 (es) 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
CN100518819C (zh) 2000-06-30 2009-07-29 阿斯比奥制药株式会社 含有人甲状旁腺激素的药物成分及含有该成分的用于鼻内给药的药物组合物
JP5042419B2 (ja) * 2001-08-15 2012-10-03 旭化成ファーマ株式会社 骨形成促進剤および骨形成促進組成物
JP4931306B2 (ja) 2001-09-27 2012-05-16 旭化成ファーマ株式会社 骨形成を安全に促進させる医薬複合剤
CN1816324A (zh) * 2003-07-04 2006-08-09 尼克麦德丹麦公司 口服用的含甲状旁腺激素(pth)的药物组合物
EP1741441A4 (en) * 2004-04-26 2010-03-03 Ono Pharmaceutical Co BONE-ENHANCING AGENT CHARACTERIZED BY USING CATHEPSIN K INHIBITOR WITH PTH
RU2006143544A (ru) * 2004-05-10 2008-06-20 Нэстек Фармасьютикал Кампани Инк. (Us) Композиции и способ для облегченной чресслизистой доставки паратиреоидного гормона
JP2006241098A (ja) * 2005-03-04 2006-09-14 Univ Kurume 骨量減少症の予防または治療薬
EP1991282B1 (en) * 2006-02-09 2013-06-19 BioMimetic Therapeutics, LLC Compositions and methods for treating bone
DE102006043846A1 (de) * 2006-03-14 2007-09-20 Claudia Zours Wirbelsäulenorthesen
CN101466393A (zh) * 2006-03-15 2009-06-24 阿尔扎公司 用于经皮递送甲状旁腺激素药剂以治疗骨质减少的方法
CN101274961A (zh) * 2006-03-30 2008-10-01 天津医科大学 重组人甲状旁腺素相关蛋白
CN101125201A (zh) * 2006-08-17 2008-02-20 石家庄欧意药业有限公司 治疗骨质疏松症或防治由于骨质疏松而导致的骨折的药物组合物及其应用
CN101307105B (zh) * 2008-04-28 2012-08-29 中国药科大学 一种能串联表达和同步酸水解释放的人甲状旁腺素1-34肽类似物及其制备方法和应用

Also Published As

Publication number Publication date
JP2017105858A (ja) 2017-06-15
KR20210040171A (ko) 2021-04-12
MX2012002681A (es) 2012-04-19
EP2476429A1 (en) 2012-07-18
NZ617397A (en) 2015-02-27
ES2663322T3 (es) 2018-04-12
EP2682125A1 (en) 2014-01-08
MX335951B (es) 2016-01-04
JP2017105862A (ja) 2017-06-15
JP6150846B2 (ja) 2017-06-21
EP2682124B1 (en) 2018-02-28
RU2564894C2 (ru) 2015-10-10
ES2843649T3 (es) 2021-07-20
WO2011030774A1 (ja) 2011-03-17
JP6043008B2 (ja) 2016-12-14
US20120252729A1 (en) 2012-10-04
KR20140130754A (ko) 2014-11-11
KR102424644B1 (ko) 2022-07-25
JP6522715B2 (ja) 2019-05-29
JP2016130261A (ja) 2016-07-21
JP6198346B2 (ja) 2017-09-20
EP2476429A4 (en) 2013-02-27
CA2772656A1 (en) 2011-03-17
JP2015157854A (ja) 2015-09-03
EP2682125B1 (en) 2020-11-04
CN102470164A (zh) 2012-05-23
NZ598370A (en) 2014-04-30
JP2015147813A (ja) 2015-08-20
JP2018024710A (ja) 2018-02-15
JP6301524B2 (ja) 2018-03-28
IL217854A (en) 2016-08-31
EP2476429B1 (en) 2018-03-07
KR20120067336A (ko) 2012-06-25
AU2010293488A1 (en) 2012-03-29
EP2682124A1 (en) 2014-01-08
CN102470164B (zh) 2014-04-09
AU2010293488B2 (en) 2014-11-27
JP6275900B2 (ja) 2018-02-07
ZA201201720B (en) 2012-11-28
US20140249084A1 (en) 2014-09-04
JP6274634B2 (ja) 2018-02-07
IN2012DN00857A (es) 2015-07-10
JP2017105861A (ja) 2017-06-15
US20140357560A1 (en) 2014-12-04
KR20190095552A (ko) 2019-08-14
JPWO2011030774A1 (ja) 2013-02-07
RU2012108635A (ru) 2013-10-20
JP2017105859A (ja) 2017-06-15
JP2017105860A (ja) 2017-06-15
KR20170089017A (ko) 2017-08-02
JP2019023234A (ja) 2019-02-14
KR20170089018A (ko) 2017-08-02
BR112012003511A2 (pt) 2019-09-24
JP2017061511A (ja) 2017-03-30
ES2662018T3 (es) 2018-04-05
JP2017105863A (ja) 2017-06-15
IL217854A0 (en) 2012-03-29
KR102335703B1 (ko) 2021-12-07
KR20200115673A (ko) 2020-10-07
KR20150021590A (ko) 2015-03-02
CN103893746A (zh) 2014-07-02

Similar Documents

Publication Publication Date Title
HK1168284A1 (en) Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units
IL234624A0 (en) Compounds for use as a drug to treat a solid tumor in a patient
PL2437829T3 (pl) Mechanizm ustawiania dawki dla urządzenia do dostarczania leku dla ograniczania ustawienia dawki odpowiadającej pozostałej ilości leku
IL239488A0 (en) A gpc3-targeted medicinal agent for the treatment of patients for whom treatment with a gpc3-targeted medicinal agent is beneficial
IL221166B (en) A system for administering medication to a patient
PT2482812T (pt) Composições farmacêuticas compreendendo bi-1356 e metformina
PL2568887T3 (pl) Urządzenie do dostarczania kompozycji leczącej tkanki do zszywanej tkanki
EP2240232A4 (en) DISPENSER AND THERAPEUTIC PACKAGE FOR THE ADMINISTRATION OF A THERAPEUTIC SUBSTANCE TO A PERSON
IL216468B (en) Pharmaceutical compounds for administration by metered dose inhaler containing glycopyrrolate and formoterol and used for the treatment of respiratory diseases
ZA201102645B (en) Method for delivering a pharmaceutical composition to patient in need thereof
IL216668A (en) Pharmaceutical preparation and its use in the preparation of a drug for emergency contraception
EP2696858A4 (en) UNIT DOSE FOR ORAL ADMINISTRATION
IL221744A (en) Use of a combination of compounds to prepare a drug to treat Parkinson's disease
IL217777A (en) A peptide for the preparation of pain medication
IL217198A0 (en) Composition for treating a patient in need of aspirin therapy
IL215826A (en) Pharmaceutical preparation with delayed release, process of preparation of the preparation, use of the preparation for the preparation of pain medication and the pill containing it.
EP2370068A4 (en) METHOD AND COMPOSITIONS FOR DELIVERING MEDICAMENTS TO THE LUNG
GB2455875B (en) A process for the preparation of an orally administered unit dose tablet
HK1199416A1 (en) A device for administering a powdered medicament to a patient by inhalation
IL217185A0 (en) Medicinal carbohydrates for treatment of respiratory conditions
IL217527A0 (en) Fulvestrant in a dosage of 500 mg for the treatment of advanced breast cancer
IL218230B (en) Use of lapatinib or an acceptable pharmaceutical salt or preparation thereof for the preparation of a drug for the treatment of cancer
GB2475701B (en) A process for the preparation of an orally administered anthelmintic unit dose tablet
IL215695A (en) Use of Compounds 1-Phenyl-3-Dimethyl Amino Propane for the preparation of rheumatic pain medication
EP2303282A4 (en) TREATMENT UTILIZING A LOW-DOSE CONTINUOUS APPLICATION OF SUGAR ANALOGS